A phase I dose escalation study of AT 9283 , a small molecule inhibitor of aurora kinases , in patients with advanced solid malignancies

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies H.-T. Arkenau , R. Plummer, L. R. Molife, D. Olmos, T. A. Yap, M. Squires, S. Lewis, V. Lock, M. Yule, J. Lyons, H. Calvert & I. Judson* Drug Development Unit, Royal Marsden NHS Foundation Trust, Surrey, London; Northern Centre for Cancer Treatment, Newcastle upon Tyne; Astex Therapeutics Ltd, Cambridge, UK

[1]  R. Plummer,et al.  A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  H. Lenz,et al.  Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer , 2011, The Pharmacogenomics Journal.

[3]  Suzanne F. Jones,et al.  Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[4]  Jason Clark,et al.  Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[5]  Arijit Chakravarty,et al.  Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics , 2010, Molecular Cancer Therapeutics.

[6]  A. Green,et al.  AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders , 2010, British journal of haematology.

[7]  M. Scheulen,et al.  A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. , 2010 .

[8]  Riccardo Spinelli,et al.  Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Suzanne F. Jones,et al.  A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[10]  T. Ouchi,et al.  Essential Roles of mTOR/Akt Pathway in Aurora-A Cell Transformation , 2009, International journal of biological sciences.

[11]  L. Fazal,et al.  Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283 , 2009, Cell cycle.

[12]  S. Sen,et al.  Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma , 2009, Head & neck.

[13]  S. Arii,et al.  Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue , 2009, Cancer science.

[14]  Mladen Vinković,et al.  Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. , 2009, Journal of medicinal chemistry.

[15]  Christopher D. Scharer,et al.  Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells , 2008, Journal of Translational Medicine.

[16]  Oliver Gautschi,et al.  Aurora Kinases as Anticancer Drug Targets , 2008, Clinical Cancer Research.

[17]  D. Bergstrom,et al.  A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Monsarrat,et al.  Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2–M transition , 2004, Journal of Cell Science.

[19]  J. Ruderman,et al.  Aurora A, Meiosis and Mitosis , 2004, Biology of the cell.

[20]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[21]  W. Earnshaw,et al.  The cellular geography of Aurora kinases , 2003, Nature Reviews Molecular Cell Biology.

[22]  Stephen S. Taylor,et al.  Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores , 2003, The Journal of cell biology.

[23]  L. Amundadottir,et al.  Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Moll,et al.  Aurora kinases and their inhibitors: more than one target and one drug. , 2008, Advances in experimental medicine and biology.

[25]  Kaori Sasai,et al.  Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 , 2004, Nature Genetics.

[26]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.